FASN and neoplasm: Inhibition of SREBP-1 downregulates FASN and ACC levels, thereby reducing palmitic acid and stearic acid synthesis and notably inhibiting cell proliferation in the BxPC-3 transplantation tumor model (Kim et al., 2022).